MHC-I neoantigenic properties of TP53 variants are associated with differences in cancer risk and spectrum in individuals with pathogenic TP53 variants, suggesting that individual variant-specific immune response could contribute to the heterogenous presentation of LFS. This evidence concerns the gene TP53 and cancer.